Secondary prophylaxis of neutropenia – pro
Primary prophylaxis with G-CSF is well established. It is less clear that it should be used for neutropenia that already ocurred, what is called secondary prophylaxis. ASCO and ESMO guidelines suggest that secondary prophylaxis with granulocyte CSFs be limited to patients who experience a neutropenic complication (ie, fever, treatment delay) from a prior cycle of chemotherapy (for which primary prophylaxis was not received) if reduced dose intensity might compromise treatment outcome
NCCN, Supportive Chemotherapy 2015
Lyman GH, Kleiner JM. Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy. Cancer Treat Res. 2011;157:145-65.
D Cameron, Management of chemotherapy-associated febrile neutropenia British Journal of Cancer (2009) 101, S18–S22.
Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015; 33:3199.
National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed on February 27, 2016).
Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol 2016; 27:v111.